PictorLabs Inc
Histopathology reimagined.
Histopathology reimagined.
PictorLabs Inc is a digital pathology company developing an AI-powered virtual staining platform to revolutionize histopathology and accelerate clinical research with the goal of improving patient outcomes. Led by a team with deep expertise in bioengineering, artificial intelligence, and health-tech product development, the Company is reimagining existing histopathology workflows, accelerating clinical and diagnostic results, and improving process sustainability. From a single unstained tissue sample, PictorLabs’ proprietary platform can produce an unlimited number of virtual stains that are indistinguishable from analogous chemical stains. PictorLabs is developing products that replicate standard of care stains and is creating specialized virtual biomarker stains for indications in which there is a large demand for novel and accelerated diagnostic tests. The company was founded in 2019 and is headquartered in the United States.
The latest milestone for PictorLabs Inc was the $30.00M Series B investment on 18 September 2024. The investors in this round were Insight Partners and MERL Ventures Fund.
To learn more about PictorLabs Inc, visit their website at https://pictorlabs.ai.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $30.00M | 2 |
|
18 Sep 2024 |
| Series A | $15.22M | 3 |
|
26 May 2022 |
| Seed Round | $3.60M | - | 07 Oct 2020 |
No recent news or press coverage available for PictorLabs Inc.
We care about your data, and we'd love to use cookies make your experience better.
